Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13221 | 1.00 | RAB9A (0.32) | RAB9AELANEPCSK9L3MBTL1NOS1 | |
| SCHEMBL14135 | 1.00 | RAB9A (0.32) | RAB9AELANEPCSK9L3MBTL1NOS1 | |
| SCHEMBL2343819 | 0.89 | ELANE (0.35) | ELANENOS1 | |
| SCHEMBL17560519 | 0.89 | ELANE (0.35) | ELANENOS1 | |
| SCHEMBL17654422 | 0.89 | RAB9A (0.32) | RAB9AELANEPCSK9L3MBTL1NOS1 | |
| SCHEMBL2127300 | 0.89 | ELANE (0.35) | ELANENOS1 | |
| SCHEMBL13518677 | 0.89 | RAB9A (0.32) | RAB9AELANEPCSK9L3MBTL1NOS1 | |
| SCHEMBL13518680 | 0.89 | RAB9A (0.32) | RAB9AELANEPCSK9L3MBTL1NOS1 | |
| SCHEMBL25504021 | 0.89 | ELANE (0.32) | ELANENOS1 | |
| SCHEMBL24177802 | 0.89 | PCSK9 (0.33) | ELANEPCSK9NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1313 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10155009-B2 | Polyion complex of poly(L-arginine) segment-containing block copolymer and polyanionic polymer | General Incorporated Association Tsukuba Global Innovation Promotion Agency (JP) | 2018-12-18 | — | — | US | claimed |
| US-20180085395-A1 | POLYION COMPLEX OF POLY(L-ARGININE) SEGMENT-CONTAINING BLOCK COPOLYMER AND POLYANIONIC POLYMER | General Incorporated Association Tsukuba Global Innovation Promotion Agency (JP) | 2018-03-29 | — | — | US | claimed |
| EP-3284474-A1 | POLYION COMPLEX OF POLY(L-ARGININE) SEGMENT-CONTAINING BLOCK COPOLYMER AND POLYANIONIC POLYMER | General Incorporated Association Tsukuba Global Innovation Promotion Agency (JP) | 2018-02-21 | — | — | EP | claimed |
| US-20150368192-A1 | A METHOD OF SYNTHESIZING CREATINE DERIVATIVES | UNIV DEGLI STUDI GENOVA (IT) | 2015-12-24 | — | — | US | claimed |
| EP-2935207-A1 | A METHOD OF SYNTHESIZING CREATINE DERIVATIVES | Universita' degli Studi di Genova (IT) | 2015-10-28 | — | — | EP | claimed |
| WO-2014097335-A1 | A METHOD OF SYNTHESIZING CREATINE DERIVATIVES | UNIVERSITA' DEGLI STUDI DI GENOVA (IT) | 2014-06-26 | — | — | WO | claimed |
| US-20050090525-A1 | Isoquinoline derivatives | MERCK PATENT GMBH (DE) | 2005-04-28 | — | — | US | claimed |
| CN-122055148-A | Conjugates, compositions and methods for treating influenza | 珀杜研究基金会 | 2026-05-15 | — | — | CN | disclosed |
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2026-04-23 | — | — | US | disclosed |
| EP-4720058-A2 | BIFUNCTIONAL DEGRADERS AND USES THEREOF | Casma Therapeutics, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260069549-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12569565-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| WO-2026044019-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLUENZA INFECTION | LOW STEWART (US) | 2026-02-26 | — | — | WO | disclosed |
| US-5714606-A | OLIGONUCLEOTIDE HAVING RECEPTOR BINDING SITES; ENZYME INHIBITORS, ANTIINFLAMMATORY AGENTS, MEDICAL DIAGNOSIS | ISIS PHARMACEUTICALS, INC. (US) | 1998-02-03 | — | — | US | disclosed |
| WO-1997011693-A1 | GUANIDINO PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1997-04-03 | — | — | WO | disclosed |
| EP-0759917-A1 | NOVEL SELECTIVE INHIBITORS OF VIRAL OR BACTERIAL NEURAMINIDASES | GILEAD SCIENCES, INC. (US) | 1997-03-05 | — | — | EP | disclosed |
| WO-1997006157-A1 | DIHYDROPYRAN DERIVATIVES AS VIRAL NEURAMINIDASE INHIBITORS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 1997-02-20 | — | — | WO | disclosed |
| WO-1996026933-A9 | NOVEL SELECTIVE INHIBITORS OF VIRAL OR BACTERIAL NEURAMINIDASES | — | 1996-11-28 | — | — | WO | disclosed |
| WO-1996036628-A1 | 6-CARBOXAMIDO DIHYDROPYRAN DERIVATIVES | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 1996-11-21 | — | — | WO | disclosed |
| WO-1996026933-A1 | NOVEL SELECTIVE INHIBITORS OF VIRAL OR BACTERIAL NEURAMINIDASES | GILEAD SCIENCES, INC. (US) | 1996-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368192-A1 | A METHOD OF SYNTHESIZING CREATINE DERIVATIVES | CKMT1A; CKMT1B, TNNI3, TNNT2 | RAB9A 2597/4885ELANE 4385/4885PCSK9 1504/4885 |
| US-20260069549-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | SIN3A, PLIN3, MSR1 | RAB9A 229/4885ELANE 1895/4885PCSK9 2183/4885 |
| US-20050090525-A1 | Isoquinoline derivatives | ITGB1, ITGB3, ITGA1 | RAB9A 1356/4885ELANE 1459/4885PCSK9 273/4885 |
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | RAB9A 2594/4885ELANE 360/4885PCSK9 1978/4885 |
| US-12569565-B2 | Compositions and methods for the treatment of viral infections | ALB, FCGR3B, FCGR1A | RAB9A 1938/4885ELANE 183/4885PCSK9 1174/4885 |
| US-10155009-B2 | Polyion complex of poly(L-arginine) segment-containing block copolymer and polyanionic polymer | ARG1, NOS2, ARG2 | RAB9A 4637/4885ELANE 2025/4885PCSK9 4231/4885 |
| US-20180085395-A1 | POLYION COMPLEX OF POLY(L-ARGININE) SEGMENT-CONTAINING BLOCK COPOLYMER AND POLYANIONIC POLYMER | ARG1, NOS2, ARG2 | RAB9A 4637/4885ELANE 2025/4885PCSK9 4231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.